- Home
- SOPH
SOPH
SOPHiA GENETICS SA
as of 06-05-2026 3:38pm EST
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
| Founded: | 2011 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 374.1M | IPO Year: | 2021 |
| Target Price: | $7.50 | AVG Volume (30 days): | 88.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $2.59 - $5.70 | Next Earning Date: | 05-05-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 23.09% | Revenue Growth (next year): | 19.57% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered SOPH Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of SOPHiA GENETICS SA (SOPH)
Chief Financial Officer
Avg Cost/Share
$4.95
Shares
20,000
Total Value
$99,000.00
Owned After
311,458
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$4.95
Shares
5,000
Total Value
$24,774.00
Owned After
250,780
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$4.60
Shares
684
Total Value
$3,149.27
Owned After
345,052
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$4.60
Shares
4,486
Total Value
$20,657.58
Owned After
3,629,495
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$4.61
Shares
608
Total Value
$2,800.39
Owned After
250,780
SEC Form 4
Chief People Officer
Avg Cost/Share
$4.60
Shares
380
Total Value
$1,747.43
Owned After
214,691
SEC Form 4
President
Avg Cost/Share
$4.60
Shares
761
Total Value
$3,501.06
Owned After
680,911
SEC Form 4
Chief Sales Officer
Avg Cost/Share
$4.54
Shares
33
Total Value
$149.90
Owned After
148,164
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| CARDOZA GEORGE | SOPH | Chief Financial Officer | Jun 5, 2026 | Buy | $4.95 | 20,000 | $99,000.00 | 311,458 | |
| Menu Philippe | SOPH | Chief Medical Officer | May 26, 2026 | Sell | $4.95 | 5,000 | $24,774.00 | 250,780 | |
| Van Well Daan | SOPH | Chief Legal Officer | May 19, 2026 | Sell | $4.60 | 684 | $3,149.27 | 345,052 | |
| Camblong Jurgi | SOPH | Chief Executive Officer | May 19, 2026 | Sell | $4.60 | 4,486 | $20,657.58 | 3,629,495 | |
| Menu Philippe | SOPH | Chief Medical Officer | May 19, 2026 | Sell | $4.61 | 608 | $2,800.39 | 250,780 | |
| Xu Zhenyu | SOPH | Chief Scientific Officer | May 19, 2026 | Sell | $4.60 | 608 | $2,797.71 | 626,280 | |
| Valente Manuela | SOPH | Chief People Officer | May 19, 2026 | Sell | $4.60 | 380 | $1,747.43 | 214,691 | |
| Muken Ross | SOPH | President | May 19, 2026 | Sell | $4.60 | 761 | $3,501.06 | 680,911 | |
| Puylaert Kevin | SOPH | Chief Sales Officer | May 19, 2026 | Sell | $4.54 | 33 | $149.90 | 148,164 | |
| Xu Zhenyu | SOPH | Chief Scientific Officer | May 13, 2026 | Sell | $4.54 | 4,000 | $18,168.40 | 626,280 |
Compare SOPH vs Leading Stocks
See how SOPH stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SOPH SOPHiA GENETICS SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.